West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
IPO Year:
Exchange: NYSE
Website: westpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $400.00 | Buy | Citigroup |
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/12/2024 | $350.00 → $390.00 | Neutral → Buy | UBS |
| 2/7/2024 | $323.00 → $536.00 | Hold → Buy | Jefferies |
| 6/16/2023 | $390.00 → $405.00 | Neutral → Buy | BofA Securities |
| 4/11/2023 | $330.00 → $400.00 | Equal-Weight → Overweight | Stephens |
| 12/14/2022 | $250.00 | Hold | Deutsche Bank |
| 11/30/2022 | $250.00 | Neutral | UBS |
| 10/28/2022 | $385.00 → $250.00 | Buy → Neutral | BofA Securities |
| 7/30/2021 | $350.00 → $475.00 | Overweight | Keybanc |
3/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
S-8 POS - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
S-8 POS - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
11-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move
EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask questions on the conference call, participants need to register in advance
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 20
EXTON, Pa., July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking questions t
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%.Reported-diluted EPS of $1.55 declined by 16.2%.Adjusted-diluted EPS of $1.56 declined by 21.2%.The Company is reaffirming full-year 2024 net sales guidance in a range of $3.000 billion
EXTON, Pa., April 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking questions
EXTON, Pa., Feb. 20, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2024 dividend of $0.20 per share. The dividend will be paid on May 1, 2024, to shareholders of record as of April 24, 2024. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps
- Conference Call Scheduled for 9 a.m. EST Today - EXTON, Pa., Feb. 15, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%.Fourth-quarter 2023 reported-diluted EPS of $1.83 grew
EXTON, Pa., Feb. 1, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2023 financial results before the market opens on Thursday, February 15, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call
EXTON, Pa., Dec. 6, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2024 dividend of $0.20 per share. The dividend will be paid on February 7, 2024, to shareholders of record as of January 31, 2024. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West he
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.
Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00
Wolfe Research initiated coverage of West Pharm with a rating of Peer Perform
UBS upgraded West Pharm from Neutral to Buy and set a new price target of $390.00 from $350.00 previously
Jefferies upgraded West Pharm from Hold to Buy and set a new price target of $536.00 from $323.00 previously
BofA Securities upgraded West Pharm from Neutral to Buy and set a new price target of $405.00 from $390.00 previously
Stephens upgraded West Pharm from Equal-Weight to Overweight and set a new price target of $400.00 from $330.00 previously
Deutsche Bank initiated coverage of West Pharm with a rating of Hold and set a new price target of $250.00
UBS initiated coverage of West Pharm with a rating of Neutral and set a new price target of $250.00
BofA Securities downgraded West Pharm from Buy to Neutral and set a new price target of $250.00 from $385.00 previously
Keybanc reiterated coverage of West Pharmaceutical Servs with a rating of Overweight and set a new price target of $475.00 from $350.00 previously
EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m. ET. A live audio webcast will be available via the Investors section of our website, www.westpharma.com. About
EXTON, Pa., Dec. 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the Company's Board of Directors has elected Janet Haugen as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors. Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the business transformation from a mainframe hardware, software and maintenance
EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PSTJefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMTStephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2024 at 10:00 AM CSTA live audio webcast of these events will be available
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move
EXTON, Pa., Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ to showcase its leadership and expertise on industry challenges and trends in packaging and containment. "With the rise of biologic drugs, injectables are the fastest growing drug segment today, bringing with it new challenges of complex molecules and treatment requirements," says Atul Pate
EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask questions on the conference call, participants need to register in advance
EXTON, Pa., Oct. 9, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that it has been awarded the Heart of Pharma Award at the 2024 CPHI Awards for its partnership with Fox Chase Cancer Center, a part of the Temple University Health System. This award recognizes companies, individuals, and initiatives which nurture philanthropic, ethical and community-based ventures. West was announced the winner during an awards ceremony on the opening night of CPHI Worldwide on October 8 in Milan, Italy.
EXTON, Pa., Oct. 7, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Milan, Italy to showcase leadership and expertise on industry challenges and trends in packaging and containment. This year, West will highlight its industry expertise through a technical-focused presentation: Examining Contamination Control Strategy in Primary Packaging as part of EU GMP Annex 1- Wednesday, October 9 | 2:15 - 2:40 p.m.Presented by Ana Kuschel,
EXTON, Pa., Sept. 5, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Global Healthcare Conference in London, UK on Wednesday, September 18, 2024, at 9:55 AM BST. A live audio webcast of the event will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximately 90 days after the events. About West West Pharmaceutical Services, Inc. is a
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 20